Video

Dr. Jain Discusses Treatment of Richter's Transformation in CLL

Author(s):

Nitin Jain, MD

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with chronic lymphocytic leukemia who have developed Richter’s transformation.

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with chronic lymphocytic leukemia (CLL) who have developed Richter’s transformation.

Richter’s transformation remains an unmet medical need, says Jain. Most of the targeted therapies for CLL have not been successful in patients with Richter’s transformation.

Checkpoint blockade is a valid concept, Jain says, as well as chimeric antigen receptor (CAR) T-cell therapies—studies of which will come out in the next few years.

Related Videos
Jian Zhang, MD
Carsten Niemann, MD, PhD, chief physician, and head of Laboratory at the Rigshospitalet Copenhagen University Hospital.
Jae Park, MD
David A. Braun, MD, PhD
Bradley McGregor, MD,
Francisco J. Hernandez-Ilizaliturri, MD, professor, oncology, Department of Medicine – Lymphoma, director, Lymphoma Research, head, Lymphoma Translational Research Lab, associate professor, Department of Immunology, Roswell Park Comprehensive Cancer Center; clinical professor, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Monica H. Vetter, MD
Ian Krop MD, PhD
Marco Davila, MD, PhD
Related Content
US FDA
January 16th 2025

Tabelecleucel BLA Receives FDA CRL in Pretreated EBV+ Post-Transplant Lymphoproliferative Disease

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Naseema Gangat, MBBS, of Mayo Clinic
January 13th 2025

Advances in PV Management Increase Hepcidin Levels and Improve Disease Burden

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Christopher Graham, MD, of University of Minnesota Medical School
January 10th 2025

Axatilimab Shakes Up cGVHD Treatment and Looks to Move to Earlier Line in Paradigm

Supriya Gupta, MD
January 9th 2025

Venetoclax Plus BTK Inhibitor–Based Combinations Represent Promising Avenue in CLL/SLL